Filgotinib for treating moderately to severely active Crohn’s disease

Filgotinib is being developed for adults with moderately to severely active Crohn’s disease. Crohn’s disease is a type of inflammatory bowel disease which can affect any part of the digestive system. Crohn’s disease causes inflammation and ulceration, which affects food digestion, nutrient absorption, and waste elimination. Symptoms include abdominal pain, diarrhoea, weight loss and fatigue. There is no cure for Crohn’s disease so treatment options focus on managing and relieving symptoms. Patients may have periods of time when they are not suffering from symptoms (remission) or have flare-ups of symptoms (relapses). Additional treatments are required for Crohn’s disease, as some patients do not respond well to some of the current therapy options.